Gaucher disease is a rare disease. It causes the abnormal storage of fatty substances. These fatty substances build up in the bones, liver, lungs, spleen and occasionally the brain. There are three types of Gaucher disease:
Gaucher disease is a genetic disease. A faulty gene limits the amount of an enzyme called glucocerebrosidase. The enzyme normally breaks down a fat called glucocerebroside. There is not enough of the enzyme to break down all of this specific fat. As a result, it builds up in the spleen, liver, lungs, bones, and brain.
A family history of Gaucher is the only known factor that increases your risk of Gaucher.
Symptoms vary across the three types of Gaucher disease. In general, the later the onset of symptoms, the less likely that symptoms will be severe.
Type I symptoms may include:
Types II and III also have additional symptoms.
In type II, rigidity and seizures may appear within the first few months of life. Dementia and intellectual disabilities may appear later. This type is usually fatal by the age of three.
In type III, the primary symptom is a slowly progressive neurologic disease. This can include seizures and mental retardation. Other symptoms are similar to type I and may appear in early childhood. People with type III Gaucher who survive through adolescence may survive until their 30s or 40s.
Your doctor will ask about symptoms and medical history. A physical exam will be done.
Your bodily fluids and tissue may be tested. This can be done with:
There is no treatment for the severe neurologic symptoms that may occur with type II and type III Gaucher.
Treatment options for type I Gaucher include:
Certain medications can be used to replace the missing enzyme. This enzyme replacement therapy will be given through regular infusions. This therapy can help reduce abnormalities in the bone, decrease liver and spleen size, and reverse some abnormal blood counts.
Medications that reduce the amount of fatty acids in the blood may be effective for people who cannot tolerate enzyme replacement therapy.
Medications may also be given for bone pain and to relieve bone crises.
A transplant is used only in patients with severe neurological symptoms.
National Gaucher Foundation
The National Gaucher Foundation of Canada
About Gaucher. Gauchers Association website. Available at: http://www.gaucher.org.uk/about_gaucher. Accessed August 13, 2013.
Gaucher disease. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php. Updated March 4, 2013. Accessed August 13, 2013.
Gaucher disease. National Gaucher Foundation website. Available at: http://www.gaucherdisease.org. Accessed August 13, 2013.
Recommendations on the diagnosis, treatment, and monitoring of Gaucher disease. Martins AM, Valadares ER, Porta G, et al. J Pediatrics. 2009;155(4 Suppl):S10-S18.
Shire announces FDA approval of VPRIV (velaglucerase alfa for injection) for the treatment of type 1 Gaucher disease. PR Newswire website. Available at: http://www.prnewswire.com/news-releases/shire-announces-fda-approval-of-vprivtm-velaglucerase-alfa-for-injection-for-the-treatment-of-type-1-gaucher-disease-85554402.html Published February 26, 2010. Accessed August 13, 2013.
3/5/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: FDA approves therapy to treat Gaucher disease. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm202288.htm. Published February 26, 2010. Accessed March 5, 2010.
Last reviewed August 2013 by Michael Woods, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.